Loading
A next-generation KRAS G12C drug that hits the active form of the protein, from the same company as daraxonrasib.
Elironrasib is a covalent tri-complex inhibitor that binds KRAS G12C in its active, GTP-bound (ON) state, unlike the first-generation drugs sotorasib and adagrasib, which trap the inactive OFF state. Hitting the active protein is intended to produce deeper, more durable responses and to overcome the adaptive RAS reactivation that limits OFF-state inhibitors. It is being tested alone and with daraxonrasib, the pan-RAS(ON) inhibitor from the same company, in non-small-cell lung cancer, colorectal cancer and the roughly 1 to 2% of pancreatic cancers that carry G12C. It is in phase 2 with no approval yet, and whether ON-state inhibition delivers a clinically meaningful advantage over the approved G12C drugs is the open question. For a newcomer, it is a next-generation KRAS G12C drug that hits the switched-on form of the protein.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Covalent tri-complex inhibitor of KRAS G12C in the GTP-bound state. Connects to KRAS.
1.Elironrasib slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Elironrasib" OR ABSTRACT:"Elironrasib" OR TITLE:"RMC-6291" OR ABSTRACT:"RMC-6291") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Elironrasib, not a curated reading list.
Shares Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors, Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS G12C-mutant colorectal cancer.
Shares RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS & RAS inhibitors, The undruggable drivers.
Shares RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC, Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors, Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors, Revolution Medicines.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK).
Shares KRAS & RAS inhibitors, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK), KRAS.